Biomedical subjects

L B Bailey

Publications and source records attributed to L B Bailey.

At least 37 records · Page 2Linked to original sources

PubMed1997

Kinetic modeling of folate metabolism through use of chronic administration of deuterium-labeled folic acid in men.

This study was conducted as an initial investigation of in vivo folate kinetics in healthy men (n = 4) and made use of a chronic-administration protocol with stable-isotope labeling. Subjects were given 0.453 mumol (200 micrograms) total folic acid in aqueous solution daily throughout the 18-wk study while they consumed self-selected folate-adequate diets. After a 2-wk pretrial period with unlabeled folic acid, subjects were given 0.227 mumol (100 micrograms) pteroyl-L-[2H4]glutamic acid/d ([2H4]folic acid) combined with 0.227 mumol nonlabeled folic acid or [2H2]pteroylhexaglutamic acid/d for the next 8 wk; then for the next 8 wk the [2H4]folic acid was withdrawn and the subjects received only nonlabeled folic acid. Little unmetabolized folic acid was excreted in urine. Isotopic enrichment of urinary folate during [2H4]folic acid administration and withdrawal was consistent with a kinetic model having a rapid turnover pool and a slow turnover pool. In contrast with previous two-pool models, provisions were made for folate turnover by urinary folate excretion (as measured here) and by fecal excretion and catabolic processes. The precision of modeling will be improved in future studies by measurement of enrichment of additional pools. However, this study shows clearly the slow turnover of the whole-body folate pool (< or = 1% per day) and the feasibility of further long-term kinetic analysis.

Adult↗

PubMed1997

Absorption of folate from fortified cereal-grain products and of supplemental folate consumed with or without food determined by using a dual-label stable-isotope protocol.

The absorption of folic acid in fortified white and whole-wheat bread, rice, or pasta or in solution was evaluated in human subjects with use of a single-dose, dual-label, stable-isotope protocol that did not involve prior loading of subjects with nonlabeled folate. In each of five sequential trials, 14 adults received a single oral dose of [13C5]folic acid in one of the four fortified cereal-grain products or in water concurrently with an intravenous injection of [2H2]folic acid. In two additional trials, subjects received oral [13C5]folic acid with or without a light breakfast meal. In all trials, urine was collected 24-36 h postdosing and the isotopic labeling of urinary folates determined. Isotope excretion ratios of urinary folates (% [13C5]folate dose/% [2H2]folate dose), which were used as criteria of absorption, indicated no significant differences among the various fortified foods and the control (P = 0.607). Because statistical power was sufficient to have detected a 50% difference from the control, these results suggest that [13C5]folic acid in these fortified cereal-grain foods was highly available. This study also suggests that fortification will contribute effectively to the folate status of the population. Consuming [13C5]folic acid after a light breakfast meal led to a small reduction in absorption relative to the control without food (P < 0.085). Between-subject variation in this protocol exceeded that observed in previous studies conducted using prior saturation of subjects with nonlabeled folic acid. We recommend that either prior saturation or multiple doses be used in future applications of this technique to improve precision.

Adult↗

PubMed1997

A dual-label stable-isotopic protocol is suitable for determination of folate bioavailability in humans: evaluation of urinary excretion and plasma folate kinetics of intravenous and oral doses of [13C5] and [2H2]folic acid.

Stable isotopic protocols for the study of folate absorption were conducted to determine the following: (1) the equivalence of the [13C5] and [2H2] forms of folic acid, and (2) the merits of short-term plasma kinetics from injected and oral doses vs. urinary excretion of [13C5] and [2H2]folates. Another objective was to evaluate the merits of protocols not involving "saturation" of subjects with nonlabeled folate. Oral administration of [13C5] and [2H2]folic acid ( approximately 500 nmol each) to adult subjects (n = 4) yielded an equivalent 24-h urinary excretion of approximately 2% of each dose (molar ratio of urinary [13C5]/[2H2]folates = 0.96 +/- 0.055; mean +/- SEM). Expression of urinary excretion as a ratio of [13C5]/[2H2]folates yielded less within-group variability than seen for absolute excretion of each form of labeled folate. In the second study, subjects received 226 nmol of [2H2]folic acid intravenously and 1010 nmol of [13C5]folic acid orally. Isotopic enrichment of plasma [2H2]folates rose rapidly and returned to near basal values by approximately 2 h postdose. In contrast, enrichment of plasma [13C5]folates was detected until 4 h after dose, whereas enrichment values were far lower than seen with [2H2]folate. Adjusting for the difference in dose, the molar response of plasma area under the curve for isotopic enrichment was 15- to 20-fold greater for injected folates. In view of this very limited short-term plasma response even with a relatively large oral dose, presumably due to hepatic first-pass uptake, these findings suggest that plasma kinetics would be of limited usefulness in assessing the relative bioavailability of nutritionally relevant oral doses of labeled folate.

Administration, Oral↗

PubMed1997

Folate status response to controlled folate intake in pregnant women.

A metabolic study (84-d) was conducted to investigate the folate status response of pregnant subjects (n = 12) during their second trimester and nonpregnant controls (n = 12) to folate intakes approximating the current (400 microg/d) and former (800 microg/d) recommended dietary allowance (RDA). The overall goal of the study was to provide metabolic data to assist in the interpretation of the current RDA for folate. Subjects were fed a controlled diet containing 120 +/- 15 microg/d (mean +/- SD) folate and either 330 or 730 microg/d synthetic folic acid. Outcome variables between and within supplementation groups were compared at steady state. Serum folate was higher (P </= 0.05) in pregnant women consuming 850 compared with 450 microg/d (44.6 +/- 13.4, 26.3 +/- 11.3 nmol/L, respectively, mean +/- SD). No differences (P > 0.05) were detected in serum folate between pregnant and nonpregnant women within the same supplementation group. Urinary 5-methyl-tetrahydrofolate excretion was greater (P </= 0.05) in pregnant women consuming 850 compared with 450 microg/d (198.0 +/- 100.4, 9.5 +/- 3.2 nmol/d, respectively). No differences (P > 0.05) in 5-methyl-tetrahydrofolate excretion were detected between pregnant and nonpregnant women within supplementation groups. Differences (P </= 0.05) were not detected in red cell folate between pregnant women consuming either 450 or 850 microg/d (1452.5 +/- 251.8, 1733.5 +/- 208.5 nmol/L, respectively) or between pregnant and nonpregnant women consuming 450 microg/d. Our data suggest that 450 microg/d (dietary folate + synthetic folic acid) is sufficient to maintain folate status in pregnant women. This level of intake equates to approximately 600 microg/d dietary equivalents, assuming 50 and 75% availability of dietary folate and synthetic folic acid consumed with meals, respectively.

Adolescent↗

PubMed1996

Bioavailability for humans of deuterium-labeled monoglutamyl and polyglutamyl folates is affected by selected foods.

Dietary folate exists mainly as polyglutamyl forms that require deconjugation by Zn-dependent pteroylpolyglutamate hydrolase prior to intestinal absorption. Because deconjugation by pteroylpolyglutamate hydrolase is an essential step in the absorption of dietary polyglutamyl folates, factors influencing the deconjugation process may affect folate bioavailability. This study was conducted to evaluate in vivo the bioavailability of [2H4]folic acid (d4-PteGlu1) and [2H2]-pteroylhexaglutamate (d2-PteGlu6) administered in solution in water or citrate buffer or added to selected foods using a single-dose, dual-label protocol. In each of six trials, healthy men (n = 7) were given a single oral dose of d2-PteGlu6 and d4-PteGlu1 (677 nmol of each form) blended into orange juice, tomatoes, lima beans, 52 mmol/L citrate (pH 4.1), or water as the control. Urine was collected for 48 h and the isotopic labeling of urinary folates used as criteria of the relative bioavailability of administered PteGlu1 and PteGlu6. Urinary excretion of d4-folates and d2-folates derived from the respective oral doses did not differ from the control in any treatment within the statistical power of this protocol. High relative bioavailability of the polyglutamyl folate was reflected by ratios of urinary d2/d4 folates of approximately 1.0 for control, tomato, lima bean and citrate buffer trials, whereas the ratio of urinary d2/d4 folates when subjects consumed orange juice was approximately 33% less than the control ratio (P < 0.05). These findings suggest that the bioavailability of polyglutamyl folates in orange juice would be partially incomplete. However, this would be compensated by the high total folate concentration of orange juice. The relation of these findings to endogenous dietary folates requires further investigation.

Administration, Oral↗

PubMed1995

Folic acid absorption in women with a history of pregnancy with neural tube defect.

Folic acid absorption was compared in nonpregnant women with a history of pregnancy with a neural tube defect (cases)(n = 10) with that of control women (n = 10) with a normal pregnancy history. [2H4]folic acid was administered in an oral dose (400 micrograms) to fasting case and control subjects after a 30-d saturation protocol involving daily ingestion of two 1-mg folic acid supplements. Serum and red blood cell folate concentrations were not different for case and control subjects before or during the saturation protocol (P > 0.05). The percentage (x +/- SD) of the oral dose of [2H4]folic acid excreted in 24-h urine collections postdose was not different (P > 0.05) for case compared with control subjects (9.05 +/- 2.25% and 11.10 +/- 3.41%, respectively). These data suggest that the absorption of folic acid routinely consumed in supplements and fortified food products is not impaired in women with a history of a pregnancy with a neural tube defect. Further case-controlled studies are needed to compare the absorption of the predominant dietary form of the vitamin.

Administration, Oral↗

PubMed1995

Zinc status is not adversely affected by folic acid supplementation and zinc intake does not impair folate utilization in human subjects.

Changes in zinc status in response to folic acid supplementation and the effect of zinc intake on folate utilization were evaluated in 12 men (20-34 y old) consuming a diet containing 3.5 or 14.5 mg zinc/d for two 25-d intervals. Deuterium-labeled folic acid (800 micrograms/d) or a placebo was administered orally during each phase. No differences in plasma zinc, erythrocyte zinc, urinary zinc, erythrocyte metallothionein or serum alkaline phosphatase, due to supplemental folic acid, were detected at either level of zinc intake. Differences in the response to folic acid supplementation, due to the level of zinc intake, were not detected for serum, erythrocyte or urinary (labeled and unlabeled) folate. Within the constraints of this short-term folic acid supplementation study, adverse effects on zinc status were not observed and our data suggest that folic acid utilization was not influenced by level of zinc intake.

Administration, Oral↗

PubMed1995

Controlled dietary folate affects folate status in nonpregnant women.

In a study designed to estimate the requirement for dietary folate in nonpregnant women, 17 women (21-27 y) consumed 200, 300, or 400 micrograms/d of total folate for 70 d which was provided by low folate conventional foods (30 micrograms) plus supplemental folic acid. Group means for initial serum and erythrocyte folate and plasma homocysteine concentrations were not significantly different. Serum and erythrocyte folate decreased relative to the initial value in the 200 micrograms/d group (43.4 +/- 12.1%, 13.6 +/- 16.6%, respectively; mean +/- SD), in contrast to an increase in the 400 micrograms/d group (16.8 +/- 52.0%, 10.2 +/- 18.5%, respectively). The final serum folate in the 200 and 300 micrograms/d groups (6.4 +/- 0.8 nmol/L, 7.3 +/- 1.1 nmol/L, respectively) was significantly lower than that of the 400 micrograms/d group (14.3 +/- 2.0 nmol/L), with evidence in the 200 micrograms/d and 300 micrograms/d groups of low ( < 6.8 nmol/L) serum folate concentrations. Differences in final erythrocyte folate did not reach statistical significance, although low values ( < 362 nmol/L) were frequent in subjects with 200 micrograms/d intake. In the 200 micrograms/d group, plasma homocysteine was negatively correlated with serum and erythrocyte folate, and final mean plasma homocysteine (12.6 +/- 1.7 mumol/L) was significantly higher than that of the 300 or 400 micrograms/d groups. Elevated plasma homocysteine levels ( > 16 mumol/L) were observed in the 200 micrograms/d group only.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

PubMed1993

Urinary excretion of deuterium-labeled folate and the metabolite p-aminobenzoylglutamate in humans.

Stable isotopic methods were employed to determine the proportion of ingested folate excreted as the metabolite p-aminobenzoylglutamate (pABG, free and N-acetyl) in urine. Adult male subjects (n = 7) were maintained on a 4.54 mumol/d (2 mg/d) folate saturation regimen. After 7 d, subjects were given a mixed oral dose containing 0.67 mumol (300 micrograms) each of bideuterofolic acid (d2) and tetradeutero-folic acid (d4). Urine was collected for the following 48 h and analyzed for folate and pABG. The extent of deuterium labeling of urinary folate and pABG was determined by gas chromatography-mass spectrometry. Urinary total pABG excretion increased less than twofold as a result of the folate saturation, whereas urinary folate increased over 10-fold. Urinary d2 and d4 folates each contained 14-15% of the respective oral doses of labeled compounds, whereas urinary d2 and d4 pABG comprised only 0.98-1.15% of the labeled doses. Molar ratios (d2/d4) of excreted folate and pABG indicated that there was no in vivo isotopic discrimination between the labeled folates. Urinary pABG accounted for 5.1 +/- 0.6% of total ingested folate, whereas labeled pABG was about 6.7-7.6% of the excretion of labeled compounds (i.e., labeled folate + pABG). This study indicated that pABG is not a major excretory product during folate supplementation, but its relative importance may increase in conditions of reduced folate nutriture.

Adult↗

PubMed1992

Relative bioavailability of deuterium-labeled monoglutamyl tetrahydrofolates and folic acid in human subjects.

The bioavailability of orally administered monoglutamyl folic acid and various (6S)-tetrahydrofolates was examined in humans with stable-isotope methods. Folic acid (PteGlu), tetrahydrofolate (H4folate), 5-formyl-H4folate, 10-formyl-H4folate, and 5-methyl-H4folate were prepared for oral administration in 3',5'-2H2 labeled (d2) form, and [glu-2H4]folic acid (d4-PteGlu) was prepared for intravenous injection. In each of five trials, fasting adult males (n = 7) on a folate saturation regimen (2 mg/d) were given a single oral dose of one of the d2-folates in apple juice, as well as an intravenous injection of d4-PteGlu as a control. Urine was collected for 48 h and the isotope labeling of urinary folates determined by mass spectrometry. Isotope excretion ratios of urinary folates were used as criteria of bioavailability (pooled SE = 0.10): PteGlu (1.53, least squares mean), 10-formyl-H4folate (1.02), 5-methyl-H4folate (0.99), 5-formyl-H4folate (0.1.13), and H4folate (0.71). These results indicate that differences exist in the bioavailability of monoglutamyl folates under these experimental conditions. This variation, whether due to differences in absorption or postabsorptive events, must be considered in quantitative studies of folate utilization with this type of protocol.

Administration, Oral↗

PubMed1992

Erythrocyte metallothionein response to dietary zinc in humans.

The response of erythrocyte metallothionein to dietary zinc in human subjects was evaluated in a controlled metabolic protocol including standard indices of zinc status. Fifteen male subjects, age 27 +/- 3.6 y, participated in a 90-d, four-phase study consisting of acclimation (7 d; 15 mg Zn/d), treatment (6 wk; either 3.2, 7.2 or 15.2 mg Zn/d), depletion (12 d; 0.55 mg Zn/d) and supplementation (30 d; self-selected diet plus 50 mg Zn/d) phases. During the treatment phase erythrocyte metallothionein decreased in the group fed 3.2 mg Zn/d. Erythrocyte metallothionein decreased during the depletion phase (46 +/- 10%) to below the normal concentration in all groups and increased in the supplementation phase. Plasma zinc concentration decreased in the group fed 3.2 mg Zn/d during the treatment phase relative to the acclimation phase. Erythrocyte zinc decreased in all groups during the depletion phase relative to the treatment phase, and then increased during the supplementation phase. These data suggest that erythrocyte metallothionein can be used as a measure of status in severe zinc depletion and that comparing the change in erythrocyte metallothionein over a 6-wk period can differentiate between low and adequate levels of dietary zinc intake.

Adult↗

PubMed1992

In vivo folate kinetics during chronic supplementation of human subjects with deuterium-labeled folic acid.

Six healthy men (22-31 y) were supplemented for 4 wk with folic acid labeled with deuterium [3',5'-2H2; 3.6 mumol/d (1.6 mg/d)] to permit evaluation of in vivo kinetics of this vitamin. Total folate in urine, serum and erythrocytes was determined by microbiological assay, and isotopic labeling of urinary and erythrocyte folate was determined by gas chromatography-mass spectrometry. During supplementation, serum folate reached maximal concentration in approximately 18 d, whereas excretion of total and deuterium-labeled folates increased rapidly and reached isotopic steady state in 1-2 wk. Isotopic labeling of erythrocyte folate increased continually over the entire supplementation period. Upon cessation of supplementation, red blood cell folate and urinary folate excretion (total and labeled) decreased linearly. The decline in total serum folate could be described with a biexponential model that yielded a slow-phase half-life of 18.7 +/- 2.3 d. This model also indicated a turnover of 4.5% of the total body folate pool per day. Pool sizes of total body folate before and after supplementation (at steady state) were calculated to be 10 mumol (4.4 mg) and 98.9 mumol (43.7 mg), respectively. These kinetic data and stable isotope methodology may be used to address a wide range of experimental questions related to folate metabolism.

Adult↗

PubMed1992

Evaluation of a new Recommended Dietary Allowance for folate.

This article analyzes the 1989 Recommended Dietary Allowance (RDAs) for folate, which are approximately 50% less than the amounts recommended previously. The RDA committee used the following types of data to estimate allowances: (a) the quantity of folate required to elicit established physiologic responses or replace daily losses corrected for bioavailability and individual variability and (b) dietary folate intake data related to prevalence of deficiency in population groups. Some studies cited by the committee evaluated the response to synthetic folate, whereas other studies used dietary folate to estimate folate requirements. Responses to these two forms of folate may differ and depend on the individual's state of folate depletion. The correction for bioavailability is an estimate based on limited data determined by various experimental approaches. Estimates of the folate content of food vary as a function of a number of factors in the method of analysis and the specific type of food consumed. Additional variables include food preparation, food losses, and nutrient interactions. For these reasons, estimates of folate intake based on computer databases may not accurately reflect folate consumed or physiologically/metabolically available folate. Assumptions that current dietary intakes of folate are sufficient to maintain status in the US population were based, in some cases, on data from population surveys not designed to assess folate status. The new RDAs for folate may not provide an adequate safety allowance for specific population groups at risk and should be reevaluated as new information evolves.

Adolescent↗

PubMed1991

Relative bioavailability of deuterium-labeled monoglutamyl and hexaglutamyl folates in human subjects.

The bioavailability of orally administered mono- and polyglutamyl folates was examined in humans by using stable-isotope methods. [3',5'-2H2]Folic acid (d2-FA) and [3',5'-2H2]pteroylhexaglutamate (d2-PteGlu6) were prepared for oral administration and (glu-2H4)folic acid (d4-FA) was prepared for intravenous (iv) injection. In two trials, adult males (n = 7) on a folate saturation regimen (2 mg/d) were given a single 677-nmol oral dose of either d2-FA or d2-PteGlu6 in apple juice along with an iv injection of 502 nmol d4-FA as a control. Urine was collected for 48 h and the isotope labeling of urinary folates determined by mass spectrometry. The excretion ratio of urinary folates (% of d2-folate dose/% of d4-folate dose) resulting from oral d2-FA and iv d4-FA was 1.45 +/- 0.10 (mean +/- SEM) whereas the ratio for oral d2-PteGlu6 and iv d4-FA was 0.67 +/- 0.04. These results indicate that the d2-PteGlu6 is available to humans as a source of folate although its bioavailability is substantially less than that of d2-FA under these conditions.

Administration, Oral↗

PubMed1991

Bioavailability of pyridoxine-5'-beta-D-glucoside determined in humans by stable-isotopic methods.

Stable-isotopic methods were employed to evaluate the utilization of dietary pyridoxine-5'-beta-D-glucoside (PN-glucoside), a major form of vitamin B-6 in plant-derived foods, as a source of available vitamin B-6 for adult men (20-35 y old, n = 5). Deuterium-labeled forms of free pyridoxine (PN) and PN-glucoside were compared using the urinary excretion of labeled forms of the vitamin B-6 metabolite 4-pyridoxic acid as the main index of absorption and metabolism. When comparing orally administered, isotopically labeled PN and PN-glucoside in separate groups of subjects, similar bioavailability was observed although within-group variability was high. A dual-label study designed to examine the bioavailability of these compounds when administered simultaneously indicated that the utilization of deuterated PN-glucoside was 58 +/- 13% (mean +/- SEM) relative to that of deuterated PN. PN-glucoside was detected in all urine samples, which provided additional evidence of incomplete metabolic utilization. In contrast, intravenously administered PN-glucoside underwent approximately half the metabolic utilization of oral PN-glucoside. These studies indicate that the bioavailability of dietary PN-glucoside, although incomplete, is substantially greater in humans than previously found in rats. In addition, the difference between oral and intravenous routes suggests a role of beta-glucosidase(s) of the intestinal mucosa, microflora, or both in the release of free PN from dietary PN-glucoside.

Administration, Oral↗

PubMed1990

Erythrocyte metallothionein as an index of zinc status in humans.

Metallothionein concentrations in erythrocyte lysates derived from human subjects were measured by an ELISA procedure. IgG obtained from serum of sheep injected with human metallothionein 1 was used in this competitive assay. Subjects were fed a semipurified zinc-deficient diet (0.7 mg of zinc per kg of diet) for an 8-day depletion period after 3 days of acclimation. Fasting plasma zinc concentrations were reduced approximately 7%. Metallothionein in the erythrocyte lysates was significantly decreased to 59% of the initial level by the end of the depletion period. Supplementation of these depleted subjects with zinc (50 mg) did not increase erythrocyte metallothionein levels within 24 hr. Daily supplementation of control subjects with zinc (50 mg/day) increased erythrocyte metallothionein to a 7-fold maximum within 7 days. These levels were reduced by 61% within 14 days after zinc supplementation was terminated. Incubation of rat [35S]metallothionein with human erythrocyte lysate showed a time-dependent increase in 35S soluble in 20% trichloroacetic acid, indicating degradation of the labeled protein, presumably via protease activity in the lysate. It is proposed that zinc supplementation induces erythrocyte metallothionein during erythropoiesis and that low zinc intake decreases synthesis and/or accelerates degradation of the protein in reticulocytes/erythrocytes. Metallothionein levels in erythrocytes may provide a useful index upon which to assess zinc status in humans.

Adult↗

PubMed1990

Stable-isotope methods for assessment of folate bioavailability.

Research was conducted to determine whether stable-isotope-labeled folates could be employed for studies of folate absorption and metabolism in human subjects. Two deuterium-labeled forms of folic acid were evaluated for simultaneous in vivo use, with quantification of relative bioavailability by measurement of urinary excretion of labeled folates. Adult male subjects (n = 11) were given saturation doses of 2 mg unlabeled folic acid/d for 7 d before the study. After an overnight fast each subject consumed 677 nmol each of 3',5'-labeled bideuterofolic acid and glutamate-labeled tetradeuterofolic acid. The 48-h urinary excretion of deuterated folates represented 5-6% of the ingested dose. The molar ratio of labeled folates in urine was not significantly different from the molar ratio in the ingested dose, which indicated equivalent absorption and metabolism of these labeled forms of the vitamin. These results support the validity of this protocol for in vivo studies of folate bioavailability.

Adult↗

PubMed1990

Folate status assessment.

This paper is a review of established methods of folate status assessment and the primary factors that increase the risk of folate deficiency, including physiological life cycle changes. The first stage of folate depletion can be assessed by measuring serum folate levels, which drop prior to tissue depletion, and which are paralleled by a reduction in red blood cell (RBC) folate. Functional changes associated with abnormalities in biochemical pathways can be monitored by the deoxyuridine suppression test. Cell division, including erythropoiesis, becomes impaired in the same time sequence as changes in biochemical functions, as evidenced by abnormal erythrocyte morphology and a reduction in hemoglobin concentration. In addition to inadequate dietary folate intake, key factors that may impair folate utilization and thus status include alcohol consumption, smoking, and specific drugs. Folate requirements may increase during various phases of the life cycle due to physiological stresses such as pregnancy and lactation. Folate status may also be compromised during adolescence and in senescence for diverse reasons that require special emphasis on factors such as biological maturity and socioeconomic status, as well as chronic use of alcohol, drugs, and smoking.

Adolescent↗